Stem cells, including inducible pluripotent stem cells, mesenchymal stem cells (MSCs) and other primary pluripotent cells, hold the potential to treat a variety of diseases. We are currently focusing on developing an allogeneic decidua stromal cells (DSCs)-based platform to treat severe immune-mediated diseases. Our pre-clinical and clinical data suggest that the immunomodulatory activity of DSCs is superior to that of MSCs.